<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00323414</url>
  </required_header>
  <id_info>
    <org_study_id>DK61732</org_study_id>
    <secondary_id>U01DK061732</secondary_id>
    <nct_id>NCT00323414</nct_id>
  </id_info>
  <brief_title>Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver</brief_title>
  <official_title>Randomized Controlled Trial of Omega-3 Fatty Acids in the Treatment of Non-Alcoholic Steatohepatitis in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-alcoholic steatohepatitis (NASH), the most severe form of liver injury in the spectrum of
      non-alcoholic fatty liver disease (NAFLD), has emerged as the major cause of chronic liver
      disease in developed countries. Among adults in the United States, the prevalence is between
      5.7% and 17%. These rates are expected to increase concurrent with the epidemics of obesity
      and type 2 diabetes mellitus, which are the major risk factors for NAFLD and NASH. In
      addition to its high prevalence, NASH is also a progressive fibrotic disease that advances to
      cirrhosis and liver related death in 20% and 12% of patients, respectively. Among NASH
      patients with cirrhosis, 40% have liver related death. Diabetics are particularly prone to
      experience these poor outcomes. No therapy has been proven effective for patients with NASH.

      The purpose of this study is to find out whether treatment with polyunsaturated fatty acids
      (eicosapentaenoic acid [EPA] combined with docosahexaenoic acid [DHA] called Opti-EPA)
      improves NASH compared to treatment with placebo pills. The placebo pills will contain corn
      oil and will be contained in a capsule, but have no medical effect on the body. The
      investigators will determine improvement in NASH from microscopic changes in the subject's
      liver tissue during 48 weeks of treatment. This means that the subject will need to have a
      liver biopsy before and after the treatment.

      Omega-3 fatty acids are a form of polyunsaturated fats, one of the four basic types of fat
      that the body gets from food. (Cholesterol, saturated fat, and monounsaturated fat are the
      others.) One's body does not make this type of fat; it comes from food sources. These fats
      are found in foods like cold water fish (tuna, salmon, and mackerel), and vegetable products
      like flaxseed oil and walnuts.

      Research shows that polyunsaturated fats are good for people. Studies have shown that it is
      good for heart health by playing a role in keeping blood cholesterol levels low, keeping
      irregular heart rhythms stable, and reducing blood pressure.

      The drug being studied, Opti-EPA, is a nutritional supplement. They do not have to be
      reviewed by the Food and Drug Administration (FDA) like medicines do. Opti-EPA is considered
      experimental in this study. This means that the United States Food and Drug Administration
      (FDA) has not approved it for use in people with nonalcoholic fatty liver disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although there is no proven effective treatment of NASH, dietary supplementation with long
      chain omega-3 polyunsaturated fatty acids (PUFA's) may be beneficial. This suggestion is
      based on three previously reported observations: first, patients with NASH consume less PUFAs
      and more saturated fats than subjects without NASH. Second, PUFAs are beneficial in patients
      with hypertension and hypertriglyceridemia. Third, PUFAs decrease lipid peroxidation and
      ameliorate hepatic steatosis in animal models of NAFLD.

      We therefore hypothesize that the administration of these PUFAs, eicosapentaenoic acid (EPA)
      and docosahexaenoic acid (DHA) will reduce hepatic fat content, inflammation and hepatic
      injury in patients with type 2 diabetes mellitus who have NASH.

      Aims

      To determine in patients with type 2 diabetes mellitus who have NASH if dietary
      supplementation with purified omega-3 fatty acids (EPA and DHA) will:

        1. Decrease the histologic severity of NASH.

        2. Alter the expression of genes important in the pathways of hepatic lipid synthesis and
           oxidation.

      Study design:

      Patients who meet the inclusion criteria will be randomized to receive omega-3 fatty acids or
      placebo. Stratified randomization will be done based on the NASH Clinical Research Network
      pathology score of 5.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Improvement of &gt;= 2 Points in NAFLD Activity Score (NAS)</measure>
    <time_frame>48 weeks</time_frame>
    <description>The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) is a score based on the liver biopsy. It represents the sum of scores for steatosis, lobular inflammation, and ballooning, and ranges from 0-8, with high scores indicating more activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Values</measure>
    <time_frame>48 weeks</time_frame>
    <description>Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) measures insulin resistance, calculated by fasting insulin (Î¼U/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405). A higher score indicates higher insulin resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Amino Transferase (AST) Levels</measure>
    <time_frame>48 weeks</time_frame>
    <description>Aspartate amino transferase (IU/dL) at 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Amino Transferase (ALT) Levels</measure>
    <time_frame>48 weeks</time_frame>
    <description>Alanine amino transferase (IU/dL) ay 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Glucose Levels</measure>
    <time_frame>48 weeks</time_frame>
    <description>Fasting blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C Levels</measure>
    <time_frame>48 weeks</time_frame>
    <description>Hemoglobin A1c</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>Polyunsaturated fatty acid (Opti-EPA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polyunsaturated fatty acid will consist of purified EPA:DHA (360 mg EPA and 240 mg DHA) 6 gelcaps-3 capsules by mouth 2x per day x 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gelcaps containing corn oil as placebo 6 capsules 3 capsules by mouth 2 x per day for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyunsaturated fatty acid (Opti-EPA)</intervention_name>
    <description>Active experimental arm to patients with diabetes mellitus and non alcoholic steatohepatitis: Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)[360 mg EPA and 240 DHA in each capsule] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks</description>
    <arm_group_label>Polyunsaturated fatty acid (Opti-EPA)</arm_group_label>
    <other_name>Fish oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo gelcaps containing corn oil identical to the PUFA gelcaps 6 capsules-3 capsules by mouth 2x per day x 48 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Corn oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (age &gt;18 years)

          -  Have type 2 diabetes mellitus with good control of blood sugar (hemoglobin A1c [HbA1c]
             &lt;7.5%) and will have been on a stable regimen of anti-diabetic agents for more than 4
             months.

          -  NASH established on liver biopsy done within 6 months prior to inclusion in the study
             as determined by established histologic criteria

        Exclusion Criteria:

          -  Cirrhosis of the liver

          -  End stage target organ damage in diabetes mellitus: advanced renal failure (serum
             creatinine &gt; 2.0 mg/dl) with or without dialysis, severe neuropathy, or advanced
             peripheral vascular disease.

          -  Any organ dysfunction with anticipated life expectancy of less than 2 years

          -  Co-existent etiologies for liver disease

          -  Significant alcohol consumption, defined as more than 30 g per day in men and more
             than 20 g per day in women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur J. McCullough, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MetroHealth Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Srinivasan Dasarathy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.jhucct.com/nash/</url>
    <description>Nonalcoholic Steatohepatitis Clinical Research Network</description>
  </link>
  <link>
    <url>http://www.digestive.niddk.nih.gov</url>
    <description>Nonalcoholic Steatohepatitis Fact sheet</description>
  </link>
  <reference>
    <citation>Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004 Mar;2(3):262-5. Erratum in: Clin Gastroenterol Hepatol. 2004 Jun;2(6):522.</citation>
    <PMID>15017611</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2006</study_first_submitted>
  <study_first_submitted_qc>May 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2006</study_first_posted>
  <results_first_submitted>August 24, 2017</results_first_submitted>
  <results_first_submitted_qc>February 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2018</results_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PUFA</keyword>
  <keyword>NASH</keyword>
  <keyword>Fatty Liver</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Nonalcoholic fatty liver disease</keyword>
  <keyword>Nonalcoholic steatohepatitis</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PUFA</title>
          <description>Purified EPA:DHA (360 mg EPA and 240 mg DHA) 6 gelcaps 3 capsules by mouth 2x per day x 48 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Gelcaps containing corn oil as placebo 6 capsules 3 capsules by mouth 2 x per day for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PUFA</title>
          <description>Purified EPA:DHA (360 mg EPA and 240 mg DHA) 6 gelcaps 3 capsules by mouth 2x per day x 48 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Gelcaps containing corn oil as placebo 6 capsules 3 capsules by mouth 2 x per day for 48 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Improvement of &gt;= 2 Points in NAFLD Activity Score (NAS)</title>
        <description>The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) is a score based on the liver biopsy. It represents the sum of scores for steatosis, lobular inflammation, and ballooning, and ranges from 0-8, with high scores indicating more activity.</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PUFA</title>
            <description>Active treatment with PUFA</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo arm of therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement of &gt;= 2 Points in NAFLD Activity Score (NAS)</title>
          <description>The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) is a score based on the liver biopsy. It represents the sum of scores for steatosis, lobular inflammation, and ballooning, and ranges from 0-8, with high scores indicating more activity.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Values</title>
        <description>Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) measures insulin resistance, calculated by fasting insulin (Î¼U/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405). A higher score indicates higher insulin resistance.</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PUFA</title>
            <description>Active treatment with PUFA</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo arm of therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Values</title>
          <description>Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) measures insulin resistance, calculated by fasting insulin (Î¼U/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405). A higher score indicates higher insulin resistance.</description>
          <units>HOMA-IR index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="10.3"/>
                    <measurement group_id="O2" value="13.1" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Amino Transferase (AST) Levels</title>
        <description>Aspartate amino transferase (IU/dL) at 48 weeks</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PUFA</title>
            <description>Active treatment with PUFA</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo arm of therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Amino Transferase (AST) Levels</title>
          <description>Aspartate amino transferase (IU/dL) at 48 weeks</description>
          <units>IU/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" spread="17.4"/>
                    <measurement group_id="O2" value="47.9" spread="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Amino Transferase (ALT) Levels</title>
        <description>Alanine amino transferase (IU/dL) ay 48 weeks</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PUFA</title>
            <description>Active treatment with PUFA</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo arm of therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Amino Transferase (ALT) Levels</title>
          <description>Alanine amino transferase (IU/dL) ay 48 weeks</description>
          <units>IU/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9" spread="30.9"/>
                    <measurement group_id="O2" value="59.6" spread="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Glucose Levels</title>
        <description>Fasting blood glucose</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PUFA</title>
            <description>Active treatment with PUFA</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo arm of therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Glucose Levels</title>
          <description>Fasting blood glucose</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.4" spread="43.7"/>
                    <measurement group_id="O2" value="123.5" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1C Levels</title>
        <description>Hemoglobin A1c</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PUFA</title>
            <description>Active treatment with PUFA</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo arm of therapy</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1C Levels</title>
          <description>Hemoglobin A1c</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="2.2"/>
                    <measurement group_id="O2" value="6.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <desc>Patient reported adverse events and abnormal laboratory tests were collected</desc>
      <group_list>
        <group group_id="E1">
          <title>PUFA</title>
          <description>Purified EPA:DHA (360 mg EPA and 240 mg DHA) 6 gelcaps 3 capsules by mouth 2x per day x 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Gelcaps containing corn oil as placebo 6 capsules 3 capsules by mouth 2 x per day for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICD 9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Post liver biopsy pain</sub_title>
                <description>End of treatment, post liver biopsy bleeding requiring blood transfusion in one and none in the other. Both patients showed evidence of perihepatic hematoma and were discharged home uneventfully</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Post liver biopsy bleeding</sub_title>
                <description>Needed 2 units blood transfusion. Discharged uneventfully and is being followed in the clinic subsequently</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>ICD 9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>No tissue</sub_title>
                <description>Liver biopsy did not yield tissue</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Srinivasan Dasarathy MD</name_or_title>
      <organization>Cleveland Clinic Foundation</organization>
      <phone>216-444-2766</phone>
      <email>dasaras@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

